Yonhap Infomax NewsJan 12
Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.
#YonhapInfomax #Celltrion #Eyedenzelt #PatentSettlement #GlobalMarket #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99424
Celltrion Accelerates Global Market Expansion for Eyedenzelt, Its Ophthalmic Treatment

Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.

Yonhap Infomax
Yonhap Infomax NewsFeb 17, 2025
Axsome Therapeutics' stock soars 55% in 2023, with Motley Fool recommending it as a buy amid patent settlement and strong sales growth prospects
#YonhapInfomax #AxsomeTherapeutics #StockSurge #PatentSettlement #SalesGrowth #MotleyFoolRecommendation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=51006
US Pharma-Biotech Firm Axsome's Stock Surges 55% This Year - 'Not Too Late to Buy'

Axsome Therapeutics' stock soars 55% in 2023, with Motley Fool recommending it as a buy amid patent settlement and strong sales growth prospects

Yonhap Infomax